TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* MDS classified by hematopathology review as WHO categories refractory anemia (RA) or refractory cytopenia with multi-lineage dysplasia (RCMD) or refractory anemia with ring sideroblasts (RARS) or refractory anemia with excess blasts (RAEB1 or RAEB2) or chronic myelo-monocytic leukemia (CMML1 or CMML2)~* Symptomatic anemia OR thrombocytopenia with a platelet count of \< 100 x 10\^9/L OR transfusion dependence for red-cells OR transfusion dependence for platelets OR absolute neutrophil count \< 1 x 10\^9/L~Exclusion~* MDS of the WHO sub-types RA or RCMD with sole 5q- abnormality on cytogenetics unless failed lenalidomide (Revlimid) therapy~* Previous treatment with decitabine~* Untreated erythropoietin deficiency defined as an erythropoietin level of \< 200 IU/L and erythropoietin replacement therapy for \< 8 weeks (erythropoietin deficiency until corrected)~* Uncontrolled infection~* Severe sepsis or septic shock~* Current pregnancy or breast feeding~* The patient is of childbearing age, and is unwilling to use contraception and has not had a tubal ligation, hysterectomy, or vasectomy , or their partner is also unwilling to use an acceptable method of contraception as determined by the investigator~* Not able to give informed consent~* Altered mental status or seizure disorder~* ALT \> 300 IU; or albumin \< 2.0 mg/dL~* Creatinine \> 2.5 mg/dl and creatinine clearance \< 60ml/min~* B12, folate, or iron deficient, until corrected~* NYHA class III/IV status~* ECOG performance status \> 2~* HIV positive or history of seropositivity for HIV~* Transformation to acute leukemia ( \>= 20% myelo-blasts in marrow aspirate)~* Any experimental agents other than the study drug decitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: decitabine (Type: EXPERIMENTAL): INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \&lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weighing at least 15 kg~* Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele~* Forced expiratory volume in 1 second (FEV1) of 40% to 105% (inclusive) of predicted normal for age, gender, and height (Knudson standards) at Screening~* Able to swallow tablets~* As judged by the investigator, parent or legal guardian and subject must have been able to understand protocol requirements, restrictions, and instructions, and the parent or legal guardian should have been able to ensure that the subject complied with, and was likely to complete, the study as planned~* Parent or legal guardian must have signed the informed consent form and corresponding assent must be obtained from the subject~* Willing to use at least 1 highly effective birth control method during the study~* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study~* Abnormal liver function ≥ 3x the upper limit of normal~* Abnormal renal function at Screening~* History of solid organ or hematological transplantation~* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening~* Use of inhaled hypertonic saline treatment~* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
- 150 mg Ivacaftor q12h (Type: EXPERIMENTAL): Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexmedetomidine for Emergence Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I or II undergoing endoscopic sinus surgery or septoplasty under general anesthesia~Exclusion Criteria:~* predicted difficult airway~* body mass index \> 35 kg/m2,~* recent upper respiratory infection~* asthma~* current smoker~* patients using angiotensin converting enzyme-inhibitors~* uncontrolled hypertension

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
- Remifentanil (Type: ACTIVE_COMPARATOR): Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced (unresectable, recurrent or metastatic) RCC~* Patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy~* Patients with an ECOG performance status of 0-2~* Patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib~* Patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice~Exclusion Criteria:~* Patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial~* Patients who have participated in any other sorafenib trial~* Patients who have had prior therapy with investigational agent(s) within the last four weeks prior to study entry~* Life expectancy of less than two months~* Patients with cardiac arrhythmias greater than grade 1 NCI CTCAE, Version 3.0~* Patients with active coronary artery disease or ischemia~* Patients with Child-Pugh class C hepatic impairment~* Patients with severe renal impairment or who require dialysis~* Patients with active uncontrolled hypertension~* Patients with recent or active bleeding diathesis

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 20-60 (older individuals excluded due to altered sleep-related circadian signaling)~* Males and females~* Shift worker~  * Minimum of three months of prior shift work~ * Will work minimum of four nights per week or 32 hours of night shift per week during study~ * Night work defined as having at least six hours of work occurring between 8 PM and 8 AM and no longer than 12 hours on shift~* Presence of DSM-5 defined Circadian Rhythm Sleep-Wake Disorder: Shift Work Type~  * Insomnia (SE \< 88%) during attempted daytime sleep or excessive sleepiness during nocturnal wake~Exclusion Criteria:~* Currently or planning to become pregnant~* Currently breastfeeding~* Inadequate opportunity (\<7 hours) for daytime sleep after shift work~* Use of sleep aids during the study period. Includes as needed or continuous use of prescription, non-prescription, and naturopathic pharmacotherapies~* Diagnosis or detection (during study) of sleep disordered breathing (AHI\>10) on home sleep testing; referral to clinical sleep program will be offered~* Diagnosis of narcolepsy~* Restless Legs Syndrome~* \>600 mg caffeine intake per night shift or use of prescription stimulant medication during night shift~* Rotational or irregular work shifts during study~* Use of digoxin for six months prior to or during study~* Use of strong (e.g., etoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin, conivaptan) or moderate (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) CYP3A inhibitors or CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin) for six months prior to or during study~* Severe hepatic impairment~* Unstable or severe medical or psychiatric condition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Drug (Type: EXPERIMENTAL): 10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pill 30 minutes prior to daytime sleep opportunity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Milrinone Versus Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age \>34 weeks~* postnatal age \<10 days~Exclusion Criteria:~* neonates with congenital heart disease~* neonates with congenital diaphragmatic hernia

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- milrinone (Type: ACTIVE_COMPARATOR): Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil.
- sildenafil (Type: ACTIVE_COMPARATOR): Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients refractory to BCG therapy;~* Patients with histologically confirmed diagnosis of high grade lesions;~* Diagnosis of high grade lesion must be within 56 days prior to beginning of study treatment;~* Have had all visible papillary lesion(s) resected by TURBT within 56 days prior to beginning of study treatment;~* Available for the whole duration of the study including follow-up (60 months);~* Life expectancy of \> 5 years;~* Patients with an ECOG performance status grade of 2 or less;~* Absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra within 12 months from beginning of study treatment;~* Able to understand and give written informed consent;~* In the investigator's judgment, the patient is able to participate in the study.~Exclusion Criteria:~* Current or previous history of muscle invasive tumors;~* Current or previous history of lymph node or distant metastases from bladder cancer;~* Current systemic cancer therapy;~* Current or prior pelvic external beam radiotherapy;~* Pelvic brachytherapy within 2 years of study entry;~* Prior treatment with MCC;~* Patients with existing urinary tract infection or recurrent severe bacterial cystitis;~* Clinically significant and unexplained elevations of liver or renal function tests;~* White blood cell count below 3 x109/L (3,000/mm3) or platelet count below 100 x 109/L(100,000/mm3);~* Severe cardiovascular disease;~* Women who are pregnant or lactating;~* Congenital or acquired immune deficiency;~* With history of malignancy of any organ system, treated or untreated, within the past 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, stage T1 prostate cancer, carcinoma in situ of the cervix or colon polyps);~* Previous investigational treatment within 3 months from beginning of study treatment;~* Patients who cannot hold the instillation for one hour;~* Patients who cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy);~* Clinically significant active infections;~* Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mycobacterial cell wall-DNA complex (Type: EXPERIMENTAL): Mycobacterial cell wall-DNA complex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Malignant, histologically proved, non resectable pleural Mesothelioma~* In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.~* ECOG Performance status 0-2~* Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)~* At least 18 years of age, less than 76 years of age~* Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days~Exclusion Criteria:~* Prior chemotherapy~* Brain metastasis~* History of cerebral vascular accident (CVA) or transient ischemic attack

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard Chemotherapy
- 2 (Type: EXPERIMENTAL): Standard Chemotherapy + bevacizumab (Avastin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must agree to undergo tumor HRD testing and blood gBRCAmut status testing.~* Patients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosed~* Patients must have histologically diagnosed high-grade (Grade 2 or 3) serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease and must have been previously treated with chemotherapy and experienced a response lasting at least 6 months to first-line platinum based therapy.~* Patients Must have completed 3 or 4 previous chemotherapy regimens.~* Patients must have completed their last chemotherapy regimen \> 4 weeks prior to treatment initiation.~* Patients must have measurable disease according to RECIST (v.1.1).~* Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary or recurrent cancer or agree to undergo fresh biopsy prior to study treatment initiation.~* Patients must agree to blood samples during screening and at the end of treatment for cytogenetic analysis.~Exclusion Criteria:~* Patients must not have any known, persistent (\> 4 weeks), ≥Grade 3 hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (\>4 weeks), ≥ Grade 3 fatigue during the last cancer therapy.~* Patients must not have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment.~* Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.~* Patients must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection.~* Patients must not have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment.~* Patients must not have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Niraparib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Peer Telephone Cessation Counseling for Smokers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The inclusion criteria: veterans who received the Tobacco Tactics intervention as an inpatient in the hospital.~Exclusion Criteria:~* The exclusion criteria: veterans who are too ill or impaired to consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peer telephone cessation counseling (Type: None): The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients from age 18 to 65 years ;~2. Male or female;~3. Treatment-naive patients of clinically diagnosed as HBV-induced compensated cirrhosis(meet one of the following two criterions);~   1. endoscopy: esophageal varices , exclusion of noncirrhotic portal hypertension~  2. if no endoscopy,should meet two of the four Criterias:~      * Imaging (US, CT or MRI, et al) showing Surface nodularity: Echogenecity~     * Platelet (PLT) \< 100×10 \< 9 \>/L , no other interpretation~     * Albumin (ALB) \< 35.0 g/L, or International Standard Value (INR) \> 1.3 (Prothrombin Time (PT) prolonged \> 3s), or Cholinesterase (CHE) decrease~     * Liver stiffness measurement value \> 12.4 kpa (ALT\<5×ULN)~4. HBeAg-positive, HBVDNA \> 2×10\<3\> IU/ml or with HBeAg-negative patients, HBVDNA \> 2×10\<2\> IU/ml;~5. Agree to be followed up regularly;~6. Signature of written inform consent.~Exclusion Criteria:~1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;~2. Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for medicine in this study;~3. Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;~4. Patients with baseline AFP level higher than 100ng/ml and possible malignant lesion on image, or AFP level higher than 100ng/ml for more than three months;~5. Creatinine \> 1.5×ULN;~6. Patients with other uncured malignant tumors;~7. Patients with severe diseases of heart, lung, kidney, brain, blood system or other organs;~8. Patients with any other reasons not suitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Entecavir Therapy (Type: ACTIVE_COMPARATOR): Entecavir, 0.5mg, qd, oral, for 2 years
- Entecavir plus thymosin therapy (Type: EXPERIMENTAL): Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete